Lakefront Biotherapeutics American Depositary Shares (LKFT) – What Are Investment Firms Saying About This Stock?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has received a consensus recommendation of “Hold” from the eight research firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $35.50.

A number of equities research analysts have recently weighed in on LKFT shares. TD Cowen began coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They issued a “buy” rating for the company. UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research note on Wednesday, September 23rd. Royal Bank Of Canada upgraded Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $26.00 to $45.00 in a report on Wednesday, September 23rd. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 2nd. Finally, Morgan Stanley assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, October 20th. They issued an “equal weight” rating and a $26.00 target price for the company.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Lakefront Biotherapeutics American Depositary Shares stock opened at $32.28 on Friday. Lakefront Biotherapeutics American Depositary Shares has a fifty-two week low of $25.68 and a fifty-two week high of $36.24. The firm has a 50 day moving average price of $29.49 and a 200 day moving average price of $29.97. The company has a market capitalization of $2.13 billion, a PE ratio of -22.89 and a beta of 0.24.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Monday, August 10th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $1.00. The firm had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $7.29 million. As a group, equities research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.26 earnings per share for the current year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds have recently added to or reduced their stakes in the business. QRG Capital Management Inc. boosted its position in Lakefront Biotherapeutics American Depositary Shares by 21.9% in the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock valued at $591,000 after buying an additional 3,535 shares during the period. ABC Arbitrage SA acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter worth $382,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the first quarter worth $248,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.